Drug Overview: Farxiga

  • ID: 4462193
  • Drug Pipelines
  • 57 pages
  • Datamonitor Healthcare
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Ono Pharmaceutical
  • MORE
Drug Overview

Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Ono Pharmaceutical
  • MORE
Product Profiles
Farxiga: Diabetic nephropathy
Farxiga: Diabetes type 1
Farxiga: Chronic heart failure (CHF)
Farxiga: Diabetes type 2

List of Figures
Figure 1: Farxiga for diabetic nephropathy - SWOT analysis
Figure 2: Drug assessment summary for Farxiga in diabetic nephropathy
Figure 3: Drug assessment summary for Farxiga in diabetic nephropathy
Figure 4: Farxiga for type 1 diabetes - SWOT analysis
Figure 5: Drug assessment of Farxiga in type 1 diabetes
Figure 6: Drug assessment of Farxiga in type 1 diabetes
Figure 7: Farxiga for chronic heart failure - SWOT analysis
Figure 8: Drug assessment summary of Farxiga for chronic heart failure
Figure 9: Drug assessment summary of Farxiga for chronic heart failure
Figure 10: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 11: Farxiga for type 2 diabetes - SWOT analysis
Figure 12: Drug assessment of Farxiga
Figure 13: Drug assessment scorecard for Farxiga compared to Januvia
Figure 14: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
Figure 15: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables
Table 1: Farxiga drug profile
Table 2: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 3: Farxiga Phase III trial in type 2 diabetes with cardiovascular disease or multiple risk factors (includes diabetic nephropathy patients)
Table 4: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 5: Farxiga drug profile
Table 6: Farxiga late-phase trials in type 1 diabetes
Table 7: Farxiga drug profile
Table 8: Farxiga Phase III trials in chronic heart failure
Table 9: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 10: Farxiga franchise products
Table 11: Farxiga drug profile
Table 12: Xigduo drug profile
Table 13: Overview of pivotal trial data for Farxiga in diabetes
Table 14: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
Table 15: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 16: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
  • Ono Pharmaceutical
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll